[ad_1]
Turkey announced the first data from China’s late-stage trial of Kexing vaccine, showing that its effectiveness has reached 91.25% and the final result is expected to be better than the results of a separate trial conducted in Brazil.The Turkish government agreed to join the ranks of Brazil to buy the Kohin vaccine. Transport was delayed earlier, but Turkish Health Minister Fahrettin Koca has confirmed that the first batch of 3 million doses of the vaccine will be available next week.
access:
[活动]Alibaba Cloud “End of the Year Ceremony for Enterprise Feitian Members”: New Users Can Get Up to 1212 Yuan Red Envelope
Joint Baidu Library Membership Activities – Add Baidu Netdisk Annual Card for just RMB 193.74
Koka stated at the press conference that Turkey is the first country to publish the results of the effectiveness of the Koxing vaccine, and Turkish media said that Koxing will postpone the results of the subsequent test until January next year to merge with other countries or regions conducting trials. Data, because Turkey cannot verify it independently. Koka also added that the first batch of Koxing vaccine was originally expected to arrive after December 11, but was delayed due to licensing issues. Now it resumed to arrive next week, with a total of 50 million doses purchased. In addition, Turkey has also reached an agreement with Pfizer and its German partner BioNTech on vaccines. He said Turkey is likely to get 4.5 million doses of vaccines by the end of March next year, and the total purchase may reach 34.5 million doses.
Turkey is a country with a relatively low infection rate in the world. According to official government statistics, an average of 22,000 new confirmed cases are added each week and the total number of deaths has reached 19,115. Serhat Unal, an infectious disease expert at the Turkish Medical Commission, said the 91.25% effectiveness of the Kexing vaccine was based on the first results of a late-stage trial in Turkey. A total of 7,371 volunteers participated in the randomized trial and emphasized that the Kexing vaccine was safe. standard. However, due to Coxing’s postponement of the results, Turkey withheld the full results, leading the Turkish people to question transparency.
When in doubt, the Turkish researchers also noted that the experiment was launched on September 14 and the published data was based on data from 1,332 volunteers. With the exception of one person with an allergic reaction, no major side effects were observed during the trial and common adverse reactions caused by the vaccine were stated to include fever, mild pain, and mild fatigue. Following positive results from Pfizer, Moderna and AstraZeneca in November, Kexing Vaccine released details of its subsequent clinical trials.
Koka also said: “We have now determined that the Koxing vaccine is effective and safe for the Turkish people, and Ankara will use this data to obtain approval for the Koxing vaccine. The results of the study show that the volunteers have minimal adverse reactions and therefore therefore, they are considered safe. ” Yes. Although there are still risks, we have seen clear images. Three of the volunteers did not have a fever or respiratory problems. We can show that they all passed the test with ease. “
Late-stage trials in Brazil exceeded the 50% effectiveness threshold. The Butantan Institute of the São Paulo State Medical Center is responsible for the late-stage trials of Coxing vaccines. As developed countries around the world buy vaccines from Western pharmaceutical companies Pfizer, and developing countries will pin their hopes on vaccines developed in China. Kexing vaccines can be stored in standard kitchens between 35 and 46 degrees Fahrenheit, making it easy to store and transport them to various regions. The São Paulo state government said that approximately 11,000 health workers from the Brazilian capital and seven other states participated in the third phase of the Coxing vaccine.
In an interview with the Wall Street Journal, Dimas Covas, director of the Butantan Institute, said: “In the clinical trial of the Coxing vaccine, more than 200 volunteers infected with the new corona pneumonia virus participated in the trial, providing the Researchers Sufficient Sample. Half of them took the Coxing vaccine and the other half took a placebo, which allowed the researchers to calculate the efficacy based on the state of the infected volunteers after taking the vaccine. The results of the third phase are from an independent committee made up of 5 scientists They will verify the validity. ”Covas refused to reveal the experts’ personal information, saying only that the experts are from countries other than China and Brazil.
Kexing has also signed supply agreements with Indonesia, Singapore, Chile and other countries, and is negotiating with the Philippines and Malaysia. According to China’s emergency use plan for specific populations at high risk of infection released in July, more than 10,000 people have been vaccinated with the Kexing vaccine. Kexing is based on traditional vaccine technology, which uses an inactivated coronavirus that cannot replicate in human cells to trigger an immune response. The vaccine developed by Pfizer and Moderna uses a new technology called synthetic messenger RNA (mRNA) to activate the immune system against the virus.
Pfizer is the first fully tested COVID-19 vaccine and has been approved for distribution in the United Kingdom and the United States. Koka said in response that Turkey will sign a purchase agreement with Pfizer and deliver 4.5 million doses of vaccine by the end of March next year, opting to buy another 30 million doses in the future.
